Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 8005-8017

  Bhattacharya, Arup ^a   Tóth, Károly ^a   Mazurchuk, Richard ^a   Spernyak, Joseph A ^a   Slocum, Harry K ^a   Pendyala, Lakshmi ^a   Azrak, Rami ^a   Cao, Shousong ^a   Durrani, Farukh A ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; FLUOROURACIL; INVOLUCRIN; IRINOTECAN; KI 67 ANTIGEN; PIMONIDAZOLE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER COMBINATION CHEMOTHERAPY; CELL DENSITY; CELL DIFFERENTIATION; CELL HYPOXIA; CONTROLLED STUDY; DRUG LABELING; DRUG RESPONSE; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HEAD CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NECK CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MICROCIRCULATION; OXYGEN; RATS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 9744260347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1306     Document Type: Article

References (45)

1. Grenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Murphy BA. New drug therapy for squamous carcinoma of the head and neck. Curr Opin Oncol 1996;8:221-26.
3. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996;23:11-20.
4. Rivory LP, Bowles MR, Robert J, Pond SM, Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52:1103-11.
5. Xu G, Zhang W, Ma MK, Mcleod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11.
6. Mathijssen RHJ, Van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of Irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
7. Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 2000;60:3717-21.
8. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against xenografts bearing human tumors. Clin Cancer Res 2004;10:1121-29.
9. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/ vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237:97-132.
10. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Investig 1998;103:159-65.
11. Dewhirst M. Angiogenesis and blood flow in solid tumors. In Teicher B, editor. Drug Resistance in Oncology. New York: Marcel Dekker; 1993. p. 3-24.
12. Braun R, Lanzen J, Dewhirst M. Fourier analysis of fluctuations of oxygen tension and blood flow in R 3230Ac tumors and muscle of rats. Am J Physiol 1999;277:H551-68.
13. Kaluz S, Kaluzova M, Stanbridge EJ. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res 2003;63:917-22.
14. Loncaster JA, Harris AL, Davidson SE, et al. Caronic anhydrase (CAIX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-99.
15. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
16. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (Bethesda) 2001;93:266-76.
17. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
18. Abramovitch R, Frenkiel D, Neeman M. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 1998;39:813-24.
19. Griffiths JR, Taylor NJ, Howe FA, et al. The response of human tumors to carbogen breathing monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997;39: 697-701.
20. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med 2002;48:980-6.
21. Al-Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;41:151-9.
22. Neeman M. Preclinical MRI experience in imaging angiogenesis. Cancer Metastasis Rev 2000;19:39-43.
23. Bernsen HJJA, Rijken PFJW, Oostendorp T, and Van der kogel AJ. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer 1995;71:721-6.
24. Boxerman GL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-66.
25. Lee S-P, Cilva AC, Kim S-G. Comparison of diffusion-weighted high-resolution CBF and spin-echo BOLD fMRI at 9.4T. Magn Reson Med 2002;47:736-41.
26. Silvennoinen MJ, Clingman CS, Golay X, Kauppinen RA, van Zijl PCM. Comparison of the dependence of blood R2 and R2* on oxygen saturation at 1.5 and 4.7 Tesla. MRM, 2003, 49:47-60.
27. Chou S-C, Azuma Y, Varia MA, Raleigh JA. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 2004;90:728-35.
28. Bradford MM. A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
29. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 1997;691:161-71.
30. lyer L, Ratain MJ. Clinical Pharmacology of Camptothecins. Cancer Chemother Pharmacol 1998;42:s31-43.
31. Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 1997;40:259-65.
32. Rogers A. Techniques of autoradiography, 3rd edition. New York: Elsevier/North-Holland Biomedical Press; 1979.
33. Hennig J, Nauerth A, Friedburg H. RARE Imaging: a fast imaging method for clinical MRI. Magn Reson Med 1986;3:823-33.
34. Hapke G, Yin M-B, Wu J, Frank C, Rustum YM. Phosphorylation of chkl at serine-345 affected by topoisomerase 1 poison SN-38. Int J Oncol 2002;21:1059-66.
35. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-89.
36. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-17.
37. Chao KSC, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu- ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
38. Brown JM, Le Q-T. Tumor hypoxia is important in radiotherapy, but how should we measure it? Int J Radiat Oncol Biol Phys 2002;54: 1299-301.
39. Kaluz S, Kaluzová M, Chrastina A, et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 2002;62:4469-77.
40. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995;72:889-95.
41. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998;25:743-50.
42. Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000;60:3683-88.
43. Chin CWS, Foss AJE, Stevens A, Lowe J. Differences in the vascular patterns of basal and squamous cell skin carcinomas explain their differences in clinical behaviour. J Pathol 2003;200:308-13.
44. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10: 2561-69.
45. Rustum YM, Cao S, Durrani FA, Fakih M. Se-(methyl) selenocysteine (MSC) and seleno-L-methionine (SLM) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity (abstract 2068). Proc Am Soc Clin Oncol 2004;23:144.